Cargando…
WP1066 suppresses macrophage cell death induced by inflammasome agonists independently of its inhibitory effect on STAT3
The compound WP1066 was originally synthesized by modifying the structure of AG490, which inhibits the activation of signal transducer and activator of transcription 3 (STAT3) by directly targeting Janus kinases (JAKs). WP1066 exhibits stronger anti‐cancer activity than AG490 against malignant gliom...
Autores principales: | Honda, Shino, Sadatomi, Daichi, Yamamura, Yasuo, Nakashioya, Kazutaka, Tanimura, Susumu, Takeda, Kohsuke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5378283/ https://www.ncbi.nlm.nih.gov/pubmed/28035720 http://dx.doi.org/10.1111/cas.13154 |
Ejemplares similares
-
Atypical Protein Phosphatases: Emerging Players in Cellular Signaling
por: Sadatomi, Daichi, et al.
Publicado: (2013) -
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma
por: Horiguchi, A, et al.
Publicado: (2010) -
WP1066 Sensitizes Oral Squamous Cell Carcinoma Cells to Cisplatin by Targeting STAT3/miR-21 axis
por: Zhou, Xuan, et al.
Publicado: (2014) -
A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma
por: de Groot, John, et al.
Publicado: (2022) -
WP1066 induces cell death in a schwannomatosis patient–derived schwannoma cell line
por: Allaf, Abdulrahman, et al.
Publicado: (2022)